The Food and Drug Administration (FDA) has approved Vyvanse (lisdexamfetamine dimesylate; Shire) for the treatment of binge-eating disorder in adults. Vyvanse, a CNS stimulant, is the first approved treatment for this condition.
Binge eating disorder is defined as recurring episodes (more than once weekly, for at least three months) of consuming a large amount of food in a short time, compared with others. It is the most common eating disorder in the United States, affecting an estimated 2.8 million adults, according to a national survey.
The efficacy of Vyvanse was demonstrated in two clinical studies (n=724) that evaluated adults with moderate-to-severe binge-eating disorder. Adults treated with Vyvanse experienced a decrease in the number of binge eating days per week and a decrease in obsessive-compulsive binge eating behaviors vs. adults taking placebo. Patients with current anorexia or bulimia nervosa; current comorbid psychiatric disorder; and cardiovascular risk factors other than obesity and smoking were excluded from the studies.
RELATED: ADHD Drug Could Potentially Treat Binge-Eating Disorder
Vyvanse, a Schedule II substance, was approved in 2007 for the treatment of attention deficit hyperactivity disorder (ADHD) in patients ages ≥6. It is not approved or recommended for weight loss.
Vyvanse is available in 10mg, 20mg, 30mg, 40mg, 50m, 60mg, and 70mg strength capsules in 100-count bottles.
For more information call (800) 828-2088 or visit Vyvanse.com.